

Dopamine Agonists Market - 2024-2033

<https://marketpublishers.com/r/D75E12470A2CEN.html>

Date: January 2026

Pages: 217

Price: US\$ 2,999.00 (Single User License)

ID: D75E12470A2CEN

Abstracts

The Dopamine Agonists Market was valued at US\$ 1,148.88 Million in 2024 and is anticipated to reach US\$ 1,732.41 Million by 2033, at a CAGR of 0.054 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Dopamine Agonists Market.

This report delivers a comprehensive overview of the Dopamine Agonists Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Dopamine Agonists Market. The Dopamine Agonists Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Dopamine Agonists Market Scope:

Key Players

Teva Pharmaceuticals Inc.

Major Highlights

This report delivers a comprehensive overview of the Dopamine Agonists Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Dopamine Agonists Market. The Dopamine Agonists Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Product Type
- 2.4. Snippet by Route of Administration
- 2.5. Snippet by Application
- 2.6. Snippet by Distribution Channel
- 2.7. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Increasing Prevalence of Parkinson's Disease
 - 3.1.1.2. Advancements in Drug Formulations
 - 3.1.1.3. Increased Diagnosis and Awareness
 - 3.1.2. Restraints
 - 3.1.2.1. Side Effects Associated with Drugs
 - 3.1.2.2. High Cost of Therapy
 - 3.1.2.3. Patent Expiry and Generic Competition
 - 3.1.3. Opportunity
 - 3.1.3.1. Precision Medicine and Targeted Therapies
 - 3.1.3.2. Expansion into Emerging Markets
- 3.2. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established leaders with the largest-selling Brand

- 4.1.3. Market leaders with established Product
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America
 - 4.3.2. Europe
 - 4.3.3. Asia Pacific
 - 4.3.4. South America
 - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Supply Chain Analysis
- 4.6. Patent Analysis
- 4.7. SWOT Analysis
- 4.8. Unmet Needs and Gaps
- 4.9. Recommended Strategies for Market Entry and Expansion
- 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.11. Pricing Analysis and Price Dynamics

5. GLOBAL DOPAMINE AGONISTS MARKET, BY PRODUCT TYPE

- 5.1. Introduction
 - 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 5.1.2. Market Attractiveness Index, By Product Type
- 5.2. Ergot-Based Dopamine Agonists
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 5.2.3. Bromocriptine
 - 5.2.4. Cabergoline
 - 5.2.5. Others
- 5.3. Non-Ergot-Based Dopamine Agonists
 - 5.3.1. Pramipexole
 - 5.3.2. Ropinirole
 - 5.3.3. Rotigotine
 - 5.3.4. Amantadine
 - 5.3.5. Apomorphine
 - 5.3.6. Fenoldopam
 - 5.3.7. Others

6. GLOBAL DOPAMINE AGONISTS MARKET, BY ROUTE OF ADMINISTRATION

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

6.1.2. Market Attractiveness Index, By Route of Administration

6.2. Oral

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Parenteral

6.4. Transdermal Patches

7. GLOBAL DOPAMINE AGONISTS MARKET, BY APPLICATION

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

7.1.2. Market Attractiveness Index, By Application

7.2. Parkinson's Disease

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Antipsychotic Agents

7.4. Hyperprolactinemia

7.5. Type 2 Diabetes

7.6. Restless Legs Syndrome (RLS)

7.7. Neuroleptic Malignant Syndrome

7.8. Others

8. GLOBAL DOPAMINE AGONISTS MARKET, BY DISTRIBUTION CHANNEL

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

8.1.2. Market Attractiveness Index, By Distribution Channel

8.2. Hospital Pharmacies

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Retail Pharmacies

8.4. Online Pharmacies

9. GLOBAL DOPAMINE AGONISTS MARKET, BY REGION

9.1. Introduction

- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
 - 9.2.1. Introduction
 - 9.2.2. Key Region-Specific Dynamics
 - 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.2.7.1. U.S.
 - 9.2.7.2. Canada
 - 9.2.7.3. Mexico
- 9.3. Europe
 - 9.3.1. Introduction
 - 9.3.2. Key Region-Specific Dynamics
 - 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.3.7.1. Germany
 - 9.3.7.2. U.K.
 - 9.3.7.3. France
 - 9.3.7.4. Spain
 - 9.3.7.5. Italy
 - 9.3.7.6. Rest of Europe
- 9.4. South America
 - 9.4.1. Introduction
 - 9.4.2. Key Region-Specific Dynamics
 - 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.4.7.1. Brazil

9.4.7.2. Argentina

9.4.7.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.7.1. China

9.5.7.2. India

9.5.7.3. Japan

9.5.7.4. South Korea

9.5.7.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

10.1. Competitive Overview and Key Market Players

10.2. Market Share Analysis and Positioning Matrix

10.3. Strategic Partnerships, Mergers & Acquisitions

10.4. Key Developments in Product Portfolios and Innovations

10.5. Company Benchmarking

11. COMPANY PROFILES (MAJOR PLAYERS)

11.1. Teva Pharmaceuticals Inc.

11.1.1. Company Overview

11.1.2. Product Portfolio

11.1.2.1. Product Description

11.1.2.2. Product Key Performance Indicators (KPIs)

11.1.2.3. Historic and Forecasted Product Sales

11.1.2.4. Product Sales Volume

12. FINANCIAL OVERVIEW

12.1. Company Revenue

12.1.1. Geographical Revenue Shares

12.1.1.1. Revenue Forecasts

12.1.2. Key Developments

12.1.2.1. Mergers & Acquisitions

12.1.2.2. Key Product Development Activities

12.1.2.3. Regulatory Approvals, etc.

12.1.3. SWOT Analysis

13. GSK PLC

13.1. UCB S.A.

13.2. Sun Pharmaceutical Industries Ltd.

13.3. Pfizer Inc.

13.4. Boehringer Ingelheim International GmbH

13.5. Wellona Pharma

13.6. Glenmark Pharmaceuticals Inc.

13.7. AdvaCare Pharma

13.8. Serum Institute of India Pvt. Ltd.

Emerging Players

1. CEREVEL THERAPEUTICS

1.1. Inhibikase Therapeutics, Inc.

1.2. Neuraly Inc

1.3. Peptron

1.4. Assumptions and Research Methodology

1.4.1. Data Collection Methods

1.4.2. Data Triangulation

1.4.3. Forecasting Techniques

1.4.4. Data Verification and Validation

2. APPENDIX

2.1. About Us and Services

2.2. Contact Us

I would like to order

Product name: Dopamine Agonists Market - 2024-2033

Product link: <https://marketpublishers.com/r/D75E12470A2CEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D75E12470A2CEN.html>